PMID- 32138757
OWN - NLM
STAT- MEDLINE
DCOM- 20200424
LR  - 20200424
IS  - 1471-2334 (Electronic)
IS  - 1471-2334 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Mar 6
TI  - Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected 
      patients with psychiatric disorders.
PG  - 196
LID - 10.1186/s12879-020-4922-2 [doi]
LID - 196
AB  - BACKGROUND: Few data are available regarding the use of direct antiviral agents 
      (DAAs) for chronic hepatitis C in psychiatric patients. The aim of the study is 
      to assess safety and outcome of DAAs in patients with psychiatric comorbidities. 
      METHODS: This retrospective, observational, single-centre study enrolled patients 
      treated with psychiatric drugs who initiated DAAs between 2015 and 2018. Patients 
      were classified into two groups: A (on anxiolitycs/antidepressant) and B (on 
      antipsychotics). Week-12 sustained virological response (SVR-12) and adverse 
      events (AEs) were evaluated. RESULTS: One hundred forty-four patients were 
      included (A:101; B:43). Patients were 49.3% males, mean age 60 years (SD +/- 13.5); 
      31.9% cirrhotic; 125 (86.8%) HCV-monoinfected and 19 (13.2%) HCV /HIV-coinfected. 
      Twenty patients (13.8%) required a change of psychiatric therapy before 
      initiation of DAA. Overall, SVR-12 was achieved in 88.2% of subjects in 
      intention-to-treat(ITT)-analysis. Lower SVR rates were observed in group B vs A 
      (79% vs 92%, p = 0.045) and in those changing psychiatric drugs vs others (8% vs 
      30%, p = 0.015). According to per-protocol (PP)-analysis, SVR-12 was achieved in 
      93/95 (97.9%) in group A versus 34/36 (94.4%) in group B (p = 0.30). At least one 
      AE occurred in 60 patients (41.6%), including 10 severe AEs, leading to 3 
      discontinuations. AEs were more frequently reported in group A (p = 0.015). 
      CONCLUSIONS: The study confirms effectiveness and safety of DAA-based treatment 
      also in this special population, even if a careful evaluation of history and 
      drug-drug interactions is warranted.
FAU - de Gennaro, Nicolo
AU  - de Gennaro N
AUID- ORCID: 0000-0003-0731-4590
AD  - Clinic of Infectious Diseases, University of Bari, University Hospital 
      Policlinico, Piazza Giulio Cesare n. 11, 70124, Bari, Italy. 
      nico84degennaro@gmail.com.
FAU - Diella, Lucia
AU  - Diella L
AD  - Clinic of Infectious Diseases, University of Bari, University Hospital 
      Policlinico, Piazza Giulio Cesare n. 11, 70124, Bari, Italy.
FAU - Monno, Laura
AU  - Monno L
AD  - Clinic of Infectious Diseases, University of Bari, University Hospital 
      Policlinico, Piazza Giulio Cesare n. 11, 70124, Bari, Italy.
FAU - Angarano, Gioacchino
AU  - Angarano G
AD  - Clinic of Infectious Diseases, University of Bari, University Hospital 
      Policlinico, Piazza Giulio Cesare n. 11, 70124, Bari, Italy.
FAU - Milella, Michele
AU  - Milella M
AD  - Clinic of Infectious Diseases, University of Bari, University Hospital 
      Policlinico, Piazza Giulio Cesare n. 11, 70124, Bari, Italy.
FAU - Saracino, Annalisa
AU  - Saracino A
AD  - Clinic of Infectious Diseases, University of Bari, University Hospital 
      Policlinico, Piazza Giulio Cesare n. 11, 70124, Bari, Italy.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200306
PL  - England
TA  - BMC Infect Dis
JT  - BMC infectious diseases
JID - 100968551
RN  - 0 (Antiviral Agents)
RN  - 0 (Central Nervous System Depressants)
SB  - IM
MH  - Aged
MH  - Antiviral Agents/adverse effects/*therapeutic use
MH  - Central Nervous System Depressants/adverse effects/therapeutic use
MH  - Coinfection/*drug therapy/epidemiology
MH  - Comorbidity
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - HIV Infections/*drug therapy/epidemiology
MH  - Hepatitis C, Chronic/*drug therapy/epidemiology
MH  - Humans
MH  - Male
MH  - Mental Disorders/*drug therapy/epidemiology
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Sustained Virologic Response
PMC - PMC7059311
OTO - NOTNLM
OT  - Antiviral treatment
OT  - HCV
OT  - Psychiatric comorbidity
OT  - SVR
COIS- The authors declare that they have no competing interests.
EDAT- 2020/03/07 06:00
MHDA- 2020/04/25 06:00
PMCR- 2020/03/06
CRDT- 2020/03/07 06:00
PHST- 2019/09/12 00:00 [received]
PHST- 2020/02/26 00:00 [accepted]
PHST- 2020/03/07 06:00 [entrez]
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2020/04/25 06:00 [medline]
PHST- 2020/03/06 00:00 [pmc-release]
AID - 10.1186/s12879-020-4922-2 [pii]
AID - 4922 [pii]
AID - 10.1186/s12879-020-4922-2 [doi]
PST - epublish
SO  - BMC Infect Dis. 2020 Mar 6;20(1):196. doi: 10.1186/s12879-020-4922-2.